Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: Results of a systematic review and meta-analysis of prospective studies

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 2277-2283

  Chen, Runzhe ^a   Wang, Fei ^a   Zhang, Hongming ^a   Chen, Baoan ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Clinical studies; Lymphoma; Monoantibody

Indexed keywords

BRENTUXIMAB VEDOTIN; ANTIBODY CONJUGATE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTHRALGIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEVER; HODGKIN DISEASE; HUMAN; HYPERGLYCEMIA; LARGE CELL LYMPHOMA; LYMPHOMA; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; T CELL LYMPHOMA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOCONJUGATES; LYMPHOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84929223848     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S83592     Document Type: Article

References (20)

1. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–3058.
2. Eichenauer DA, Böll B, Diehl V. Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives. Expert Opin Pharmacother. 2014;15(8):1139–1151.
3. Zinzani PL, Viviani S, Anastasia A, et al. Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica. 2013;98(8):1232–1236.
4. Dinner S, Advani R. Targeted therapy in relapsed classical hodgkin lymphoma. J Natl Compr Canc Netw. 2013;11(8):968–976.
5. Garciaz S, Coso D, Peyrade F, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin’s lymphoma. Hematol Oncol. 2014;32(4): 187–191.
6. Ansell SM. Brentuximab vedotin. Blood. 2014;124(22):3197–3200.
7. Younes A. Brentuximab vedotin for the treatment of patients with Hodgkin lymphoma. Hematol Oncol Clin North Am. 2014;28(1):27–32.
8. Deng C, Pan B, O’Connor OA. Brentuximab vedotin. Clin Cancer Res. 2013;19(1):22–27.
9. DeVita MD, Evens AM, Rosen ST, Greenberger PA, Petrich AM. Multiple successful desensitizations to brentuximab vedotin: a case report and literature review. J Natl Compr Canc Netw. 2014;12(4): 465–471.
10. Rothe A, Sasse S, Goergen H, et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood. 2012;120(7):1470–1472.
11. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (London, England). 2010;8(5):336–341.
12. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis [webpage on the Internet]. Ottawa Hospital Research Institute. (2011) Available from: www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 25 November 2012.
13. Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560–568.
14. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196.
15. Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236–1243.
16. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–3100.
17. Ogura M, Tobinai K, Hatake K, et al. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105(7):840–846.
18. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9): 1394–1402.
19. Bhatt S, Ashlock BM, Natkunam Y, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013;122(7):1233–1242.
20. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379–6381.